Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/61308
Type
ArticleCopyright
Restricted access
Embargo date
3100-12-31
Collections
Metadata
Show full item record
HALF DOSE CHADOX1 NCOV-19 VACCINE WAS EQUIVALENT TO FULL DOSES TO REDUCE MODERATE AND SEVERE COVID-19 CASES
Author
Galvão-Lima, Leonardo J.
Medeiros Júnior, Nésio Fernandes de
Jesus, Galileu S.
Morais, Antônio H. F.
Caldeira-Silva, Gleyson J. P.
Santos, João Paulo Queiroz dos
Rocha, Marcella
Santos, Marquiony Marques dos
Freire, Pierre A.
Silva, Rodrigo D.
Gouvea, Maria da Penha Gomes
Pinto Neto, Lauro Ferreira
Domingues, Carla Magda Allan Santos
Carvalho, Andréa Teixeira de
Martins Filho, Olindo Assis
Valim, Valéria
Valentim, Ricardo A. M.
Medeiros Júnior, Nésio Fernandes de
Jesus, Galileu S.
Morais, Antônio H. F.
Caldeira-Silva, Gleyson J. P.
Santos, João Paulo Queiroz dos
Rocha, Marcella
Santos, Marquiony Marques dos
Freire, Pierre A.
Silva, Rodrigo D.
Gouvea, Maria da Penha Gomes
Pinto Neto, Lauro Ferreira
Domingues, Carla Magda Allan Santos
Carvalho, Andréa Teixeira de
Martins Filho, Olindo Assis
Valim, Valéria
Valentim, Ricardo A. M.
Affilliation
Federal University of Rio Grande do Norte. Hospital Universitário Onofre Lopes. Laboratory of Technological Innovation in Health. Natal, RN, Brazil.
Universidade Federal do Espírito Santo. Programa de Pós-Graduação em Saúde Coletiva. Vitória, ES, Brazil.
Federal University of Rio Grande do Norte. Hospital Universitário Onofre Lopes. Laboratory of Technological Innovation in Health. Natal, RN, Brazil.
Federal University of Rio Grande do Norte. Hospital Universitário Onofre Lopes. Laboratory of Technological Innovation in Health. Natal, RN, Brazil / Advanced Nucleus of Technological Innovation. Federal Institute of Rio Grande do Norte. Natal, RN, Brazil.
Federal University of Rio Grande do Norte. Hospital Universitário Onofre Lopes. Laboratory of Technological Innovation in Health. Natal, RN, Brazil.
Federal University of Rio Grande do Norte. Hospital Universitário Onofre Lopes. Laboratory of Technological Innovation in Health. Natal, RN, Brazil / Advanced Nucleus of Technological Innovation. Federal Institute of Rio Grande do Norte. Natal, RN, Brazil.
Federal University of Rio Grande do Norte. Hospital Universitário Onofre Lopes. Laboratory of Technological Innovation in Health. Natal, RN, Brazil.
Federal University of Rio Grande do Norte. Hospital Universitário Onofre Lopes. Laboratory of Technological Innovation in Health. Natal, RN, Brazil.
Federal University of Rio Grande do Norte. Hospital Universitário Onofre Lopes. Laboratory of Technological Innovation in Health. Natal, RN, Brazil.
Federal University of Rio Grande do Norte. Hospital Universitário Onofre Lopes. Laboratory of Technological Innovation in Health. Natal, RN, Brazil.
Universidade Federal do Espírito Santo Programa de Pós Graduação em Saúde Coletiva. Vitória, ES, Brazil/Hospital Universitário Cassiano Antônio Moraes. Vitória, ES, Brazil.
Santa Casa de Misericórdia de Vitória. Escola Superior de Ciências. Vitória, ES, Brazil.
Pan-American Health Organization Consultant. Brasília, DF, Brazil.
Fundação Oswaldo Cruz. Instituto René Rachou. Grupo Integrado de Pesquisas em Biomarcadores. Belo Horizonte, MG, Brazil.
Fundação Oswaldo Cruz. Instituto René Rachou. Grupo Integrado de Pesquisas em Biomarcadores. Belo Horizonte, MG, Brazil.
Universidade Federal do Espírito Santo. Programa de Pós-Graduação em Saúde Coletiva. Vitória, ES, Brazil/Empresa Brasileira de Serviços Hospitalares. Hospital Universitário Cassiano Antônio Moraes. Vitória, ES, Brazil.
Federal University of Rio Grande do Norte. Hospital Universitário Onofre Lopes. Laboratory of Technological Innovation in Health. Natal, RN, Brazil.
Universidade Federal do Espírito Santo. Programa de Pós-Graduação em Saúde Coletiva. Vitória, ES, Brazil.
Federal University of Rio Grande do Norte. Hospital Universitário Onofre Lopes. Laboratory of Technological Innovation in Health. Natal, RN, Brazil.
Federal University of Rio Grande do Norte. Hospital Universitário Onofre Lopes. Laboratory of Technological Innovation in Health. Natal, RN, Brazil / Advanced Nucleus of Technological Innovation. Federal Institute of Rio Grande do Norte. Natal, RN, Brazil.
Federal University of Rio Grande do Norte. Hospital Universitário Onofre Lopes. Laboratory of Technological Innovation in Health. Natal, RN, Brazil.
Federal University of Rio Grande do Norte. Hospital Universitário Onofre Lopes. Laboratory of Technological Innovation in Health. Natal, RN, Brazil / Advanced Nucleus of Technological Innovation. Federal Institute of Rio Grande do Norte. Natal, RN, Brazil.
Federal University of Rio Grande do Norte. Hospital Universitário Onofre Lopes. Laboratory of Technological Innovation in Health. Natal, RN, Brazil.
Federal University of Rio Grande do Norte. Hospital Universitário Onofre Lopes. Laboratory of Technological Innovation in Health. Natal, RN, Brazil.
Federal University of Rio Grande do Norte. Hospital Universitário Onofre Lopes. Laboratory of Technological Innovation in Health. Natal, RN, Brazil.
Federal University of Rio Grande do Norte. Hospital Universitário Onofre Lopes. Laboratory of Technological Innovation in Health. Natal, RN, Brazil.
Universidade Federal do Espírito Santo Programa de Pós Graduação em Saúde Coletiva. Vitória, ES, Brazil/Hospital Universitário Cassiano Antônio Moraes. Vitória, ES, Brazil.
Santa Casa de Misericórdia de Vitória. Escola Superior de Ciências. Vitória, ES, Brazil.
Pan-American Health Organization Consultant. Brasília, DF, Brazil.
Fundação Oswaldo Cruz. Instituto René Rachou. Grupo Integrado de Pesquisas em Biomarcadores. Belo Horizonte, MG, Brazil.
Fundação Oswaldo Cruz. Instituto René Rachou. Grupo Integrado de Pesquisas em Biomarcadores. Belo Horizonte, MG, Brazil.
Universidade Federal do Espírito Santo. Programa de Pós-Graduação em Saúde Coletiva. Vitória, ES, Brazil/Empresa Brasileira de Serviços Hospitalares. Hospital Universitário Cassiano Antônio Moraes. Vitória, ES, Brazil.
Federal University of Rio Grande do Norte. Hospital Universitário Onofre Lopes. Laboratory of Technological Innovation in Health. Natal, RN, Brazil.
Abstract
Objectives: Previously, we presented the effectiveness of ChAdOx1 nCoV-19 half-dose (HD) immunization for preventing new COVID-19 cases. Here, we evaluated the administration of an HD of ChAdOx1 nCoV-19 in the primary immunization protocol (up to two doses) in reducing moderate and severe cases, hospitalizations, and deaths when compared to the administration of full doses (FD) after a long-term follow-up.
Methods: We evaluated data from 29,469 participants between January 2021 and November 2022 who received an HD or FD vaccine and crossed this information with their medical records to identify those who developed moderate or severe cases. All participants were classified into four groups according to their immunization status and followed 500 days after the last vaccine administration. Results: The propensity-score matching analysis indicates that the administration of the two HDs of ChAdOx1 nCoV-19 was equivalent to the use of two FDs to reduce moderate and severe COVID-19 cases. The relative risk of being infected and developing moderate or severe conditions after the administration of at least one HD or FD was similar 150 or 500 days after the administration of the immunizers. Conclusion: Administering two HDs can be used safely as a cost-effective alternative to the primary immunization protocol.
Share